Clinical Trial

Regression of Cervical Precancerous Lesions and Associated Risk Factors

Study acronym: RECER
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 25, 2026 (before its estimated July 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The aim of this study is to assess the extent of histopathological regression of severe cervical precancerous lesions (CIN 2 and CIN 3); evaluate the proportion of patients who experience the normalization of HPV test and cytology finding among those who were treated conservatively and those who underwent conization; and identify predictive parameters associated with regression. Based on this analysis, a model will be proposed to predict the likelihood of lesion regression.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-11-24.
Trial Details
NCT Number NCT06147388
Lead Sponsor General University Hospital, Prague
Conditions Cervix Uteri SIL, HPV, CIN2, CIN3
Enrollment 300 participants
Start Date 2022-09-01
Primary Completion 2026-07-01 (estimated)
Study Completion 2027-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-25